Journal article
Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States
American journal of hematology, Vol.89(7), pp.714-720
07/2014
DOI: 10.1002/ajh.23726
PMCID: PMC4069221
PMID: 24753070
Abstract
Non-Hodgkin lymphoma arising in the context of immunosuppression is an important adverse outcome after solid organ transplantation. Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed subtype of post-transplantation non-Hodgkin lymphoma, but few studies of transplant recipients have examined subtype-specific risks. Therefore, we examined DLBCL risk in the Transplant Cancer Match Study, including registry-based cancer ascertainment among 96,615 solid organ transplants performed from 2000 to 2008. We determined standardized incidence ratios (SIRs) and 95% confidence intervals comparing DLBCL risk in transplant recipients with that in the general population, and used multivariable Poisson regression models to assess the impact of potential risk factors. We identified 321 incident cases of DLBCL, over 12 times more than expected based on general population rates (SIR = 12.6, 95% confidence interval = 11.2-14.0). SIRs were highest in young recipients and those receiving a lung or pancreas/kidney-pancreas transplant, and were greatly elevated for extranodal DLBCLs at the site of the transplantation compared with other sites. DLBCL risk was highest in the first year following transplantation, and SIRs for early-onset DLBCL risk were elevated in association with Epstein-Barr virus-negative serostatus and use of polyclonal antibody induction therapy. In conclusion, associations between recipient and transplant factors and post-transplantation DLBCL risk suggest a complicated interrelationship among multiple risk factors and timing of disease.
Details
- Title: Subtitle
- Risk of diffuse large B-cell lymphoma after solid organ transplantation in the United States
- Creators
- Todd M Gibson - Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Cancer Prevention Fellowship Program, Division of Cancer Prevention, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Bethesda, MarylandEric A EngelsChristina A ClarkeCharles F LynchDennis D WeisenburgerLindsay M Morton
- Resource Type
- Journal article
- Publication Details
- American journal of hematology, Vol.89(7), pp.714-720
- DOI
- 10.1002/ajh.23726
- PMID
- 24753070
- PMCID
- PMC4069221
- NLM abbreviation
- Am J Hematol
- ISSN
- 0361-8609
- eISSN
- 1096-8652
- Publisher
- United States
- Grant note
- 5U58DP000824-04 / NCCDPHP CDC HHS U58DP000832 / NCCDPHP CDC HHS N01PC35142 / NCI NIH HHS HHSN261201000024C / NCI NIH HHS U58 DP000807 / NCCDPHP CDC HHS U58 DP000824 / NCCDPHP CDC HHS HHSN261201000036C / NCI NIH HHS U58 DP003875 / NCCDPHP CDC HHS 5U58DP000812-03 / NCCDPHP CDC HHS N01PC35137 / NCI NIH HHS U58 DP000812 / NCCDPHP CDC HHS Intramural NIH HHS U58 DP000832 / NCCDPHP CDC HHS HHSN261201000035C / NCI NIH HHS U58 DP000805 / NCCDPHP CDC HHS N01-PC-35143 / NCI NIH HHS 5U58DP003875-01 / NCCDPHP CDC HHS 1U58 DP000807-01 / NCCDPHP CDC HHS U58 DP000848 / NCCDPHP CDC HHS N01-PC-35137 / NCI NIH HHS HHSN261201000034C / NCI NIH HHS N01-PC-20100-027. / NCI NIH HHS U58DP0038789 / NCCDPHP CDC HHS N01-PC-35142 / NCI NIH HHS N01PC35139 / NCI NIH HHS P30 CA086862 / NCI NIH HHS DP000805-04 / NCCDPHP CDC HHS HHSN261201000037C / NCI NIH HHS HHSN261201000032C / NCI NIH HHS HHSN261201000027C / NCI NIH HHS N01PC35143 / NCI NIH HHS N01-PC-35139 / NCI NIH HHS HHSN261201000026C / NCI NIH HHS 1US58/DP0039311-01 / NCCDPHP CDC HHS U58 DP000848-04 / NCCDPHP CDC HHS HHSN261201000035I / NCI NIH HHS
- Language
- English
- Date published
- 07/2014
- Academic Unit
- Epidemiology
- Record Identifier
- 9983995148702771
Metrics
25 Record Views